Peptides DB
Research-centric peptide and protocol reference hub

Teduglutide record · updated 12h ago

Healing & recoveryMetabolic & appetiteGrade A · human clinicalResearch use only
All 7 studiesJump to the evidenceCompare
What is Teduglutide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: GLP-2 receptor agonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where Teduglutide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 49 registered trials. It describes the research record, not a recommendation.

Identity
NameTeduglutide
Chain length—
Molecular weight3,752.1 Da
FormulaC164H252N44O55S
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 16139605. No verified residue count for this compound.

Pharmacology
MechanismGLP-2 receptor agonist
RouteSubcutaneous injection
Half-life~7 hours
Time to peak1–2 hours
Duration24 hours
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 28, 2026. How this works →
Research stats
Total studies7
Human / animal / cellular5 / 1 / 0
Highest trial phase—
Years covered2024–2026
Latest study1mo ago
Publication history
20242026
Research funding
—no NIH grants found
Safety signals
FAERS reports9,178
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

7 rowsOpen in the library →
StudyTypeYearSummary depth
Management of Short Bowel Syndrome/Chronic Intestinal Failure – the Experience of a Single Portuguese Center
FindingMedian time of HPN for eight patients alive was 173 months.
Human2024Full text read0.80
Impact of Teduglutide on Pediatric Short Bowel Syndrome: Protocol for a Systematic Review and Trial Sequential Meta-Analysis
FindingNot reported in abstract.
review2025Title only0.30
Teduglutide in Enterocolitis Secondary to Graft-Versus-Host Disease Post-Bone Transplant: Case Report
FindingNot reported in abstract.
Human2026Full text read0.80
GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice.
FindingNot reported in abstract.
Animal2025Partial text0.60
Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.
FindingNot reported in abstract.
Human2026Full text read0.80
Successful treatment with teduglutide in short bowel syndrome with intestinal failure secondary to small-bowel volvulus: a case report and literature review.
FindingStool frequency decreased to 3-5 times per day after 4 months of teduglutide treatment.
Human2026Full text read0.70
Safety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome: a multicenter, post-marketing cohort study.
FindingMean percent reduction in parenteral calories was 49.5% by 3 years.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Teduglutide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Teduglutide is discussed should be drawn from it.